Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.

Viera SandeckáLuděk PourIvan ŠpičkaJiří MinaříkJakub RadochaTomáš JelínekAdriana HeindorferPetr PavlíčekMichal SýkoraAlexandra JungováPetr KesslerMarek WróbelDavid StarostkaJana UllrychováLukáš StejskalMartin StorkJan StraubTomáš PikaLucie BrožováSabina SevcikovaVladimír MaisnarRoman Hájek

Published in: European journal of haematology (2021)

Our study confirmed that bortezomib-based treatment is effective and safe in NDMM transplant ineligible patients, especially VMP, which was identified as superior between bortezomib-based induction regimens not only in clinical trials, but also in real clinical practice.

Keyphrases

newly diagnosed
multiple myeloma
stem cell transplantation
end stage renal disease
clinical trial
clinical practice
stem cells
low dose
bone marrow
machine learning
patient reported outcomes
randomized controlled trial
phase iii
open label
patient reported